Bill Calvin Isaacs, MD | |
817 Hillside Avenue, Canadian, TX 79014 | |
(806) 323-9307 | |
Not Available |
Full Name | Bill Calvin Isaacs |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 45 Years |
Location | 817 Hillside Avenue, Canadian, Texas |
Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1962528596 | NPI | - | NPPES |
033060701 | Medicaid | TX |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | F4112 (Texas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Hemphill County Hospital | Canadian, TX | Hospital |
Baptist St Anthony's Hospital | Amarillo, TX | Hospital |
Mailing Address | Practice Location Address |
---|---|
Bill Calvin Isaacs, MD 817 Hillside Avenue, Canadian, TX 79014 Ph: (806) 323-9307 | Bill Calvin Isaacs, MD 817 Hillside Avenue, Canadian, TX 79014 Ph: (806) 323-9307 |
News Archive
MR Solutions, with offices in the UK and Boston, will be showing their latest state of the art 3T to 9.4T superconducting, cryogen-free MRI imaging technology with optional PET and SPECT imaging modalities on stand 407 at the 16th annual World Preclinical Congress in Boston on June 13th to 15th. The congress focusses on the very latest trends and technologies impacting the preclinical drug discovery and development world.
Pharmacyclics, Inc. today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib have been selected for oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012 in Chicago, IL.
Silence Therapeutics plc announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO).
BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).
Zafgen, Inc., the world's first biopharmaceutical company dedicated to addressing the unmet need of severely obese patients, today announced new data from two Phase 1 studies of beloranib, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed significant weight loss and improvements in cardiometabolic risk markers in severely obese women.
› Verified 7 days ago
Malouf Abraham Jr., M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 604 Main Street, Canadian, TX 79014 Phone: 806-323-6554 Fax: 806-323-9001 | |
George A Cook, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1010 S 4th St, Canadian, TX 79014 Phone: 806-323-8882 Fax: 806-323-6108 | |
Roy B Kendrick, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1025 S 3rd St, Canadian, TX 79014 Phone: 806-323-8882 Fax: 806-323-6108 | |
Valerie Heather Verbi, M.D. Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 817 Hillside Avenue, Canadian, TX 79014 Phone: 806-323-9307 |